Cost-Utility Analysis of Adjuvant Therapies for Breast Cancer in Iran

International Journal of Technology Assessment in Health Care - United Kingdom
doi 10.1017/s0266462312000049
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Cambridge University Press (CUP)

Related search

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Pcn181 - Cost-Utility Analysis of Adjuvant Pertuzumab-Based Regimen in Women With Her2-Positive Breast Cancer in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cyclophosphamide and Tamoxifen as Adjuvant Therapies in the Management of Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1988English

Cost Considerations in Determining the Affordability of Adjuvant Trastuzumab in Breast Cancer

South African Medical Journal
Medicine
2016English

Adjuvant Chemoradiotherapy for Gastric Cancer: Efficacy and Cost-Effectiveness Analysis

Frontiers in Oncology
Cancer ResearchOncology
2019English

Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study

PLoS ONE
Multidisciplinary
2015English

PCN114 Cost Effectiveness of Adjuvant Cyclophosphamide in the Treatment of Breast Cancer in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Adjuvant Chemotherapy for Early Breast Cancer.

BMJ
1983English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy